G. Vratsanos

发表

Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis.

M. Weisman, L. Moreland, P. Durez, 2006, The Journal of rheumatology.

Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice.

J. Flynn, S. Nadler, C. Bigbee, 2007, Arthritis and rheumatism.

Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial

H. Genant, J. Kremer, C. Peterfy, 2007, Annals of the rheumatic diseases.

Cd4+ T Cells from Lupus-Prone Mice Are Hyperresponsive to T Cell Receptor Engagement with Low and High Affinity Peptide Antigens

J. Craft, Sungsoo Jung, G. Vratsanos, 2001, The Journal of experimental medicine.

Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study

A. Radjenovic, P. Emery, G. Firestein, 2008, Annals of the rheumatic diseases.

Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects

L. Tay, G. Vratsanos, R. Raymond, 2007, Arthritis research & therapy.

of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study.

A. Radjenovic, P. Emery, G. Firestein, 2009 .

Buch, M. H. et al. (2009) Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging

A. Radjenovic, P. Emery, G. Firestein, 2009 .

P31 Abatacept increases the proportion of patients who remain free from structural damage progression through 5 years in methotrexate inadequate responders with RA

J. Kremer, C. Peterfy, R. Westhovens, 2009 .

Surface CD152 (CTLA-4) Expression and Signaling Dictates Longevity of CD28null T Cells1

G. Burmester, S. Nadler, B. Bröker, 2009, The Journal of Immunology.

Extended Report

M. Dougados, H. Genant, I. Logeart, 2022 .

SAT0082 ASSOCIATIONS OF BASELINE CLINICAL AND BIOMARKER FACTORS WITH SYMPTOMS AND FUTURE DEVELOPMENT OF CLINICALLY-APPARENT RHEUMATOID ARTHRITIS IN AN ACPA POSITIVE COHORT

W. Robinson, G. Firestein, D. Boyle, 2019, SATURDAY, 15 JUNE 2019.